Yonsei Med J.  2023 Aug;64(8):489-496. 10.3349/ymj.2022.0406.

Surgical Treatment of Prolactinomas: Potential Role as a First-Line Treatment Modality

• Kim EH
• Kim J
• Ku CR
• Lee EJ
• Kim SH

• KMID: 2544917
• DOI: http://doi.org/10.3349/ymj.2022.0406

Abstract

Purpose
Treatment with dopamine agonists (DAs) has been the first-line standard treatment for prolactinoma, and surgery has been reserved for drug intolerance and resistance for several decades. We evaluated whether surgery plays a primary role in prolactinoma management.
Materials and Methods
We conducted a retrospective study of 210 prolactinoma patients who had received surgical treatment at our institution. We analyzed the treatment outcomes according to tumor extent, sex, and preoperative DA medication.
Results
Overall hormonal remission was achieved in 164 patients (78.1%), and complete removal was achieved in 194 patients (92.4%). When the tumors were completely removed, the remission rate increased to 84.5%. Anterior pituitary function was normalized or improved in 94.6% of patients, whereas only 4.1% of patients showed worsening of hormone control. Hormonal remission was higher in patients who had not received DA preoperatively than in those who had received preoperative DA treatment. Smaller tumor size (<1 cm), no invasion into the cavernous sinus, and female sex were predictors of good surgical outcomes.
Conclusion
Although DAs remain the first-line standard treatment for prolactinomas, surgery can be an excellent option and should be considered as an alternative primary treatment modality when patients are predicted to achieve a good surgical outcome.

Keyword

Dopamine agonist; pituitary adenoma; prolactinoma; transsphenoidal surgery